The first batch of A/H1N1 flu vaccines officially rolled off the production line of Hualan Biological Engineering Inc, a large-scale national bio-pharmaceutical company, on September 10.

Under the directions of the Ministry of Industry and Information Technology of the People’s Republic of China, the vaccines have been transported to eight provinces, including Shandong.

On September 4, the State Food and Drug Administration approved Hualan’s application for the registration of the A/H1N1 flu vaccine. On the same day, Hualan received an order from the Ministry of Industry and Information Technology to produce 4 million doses of A/H1N1 flu vaccine.

In order to meet China’s potential needs to fight against A/H1N1 influenza, Hualan Biological Engineering Inc said 13 million doses of vaccine would be produced before the National Day Holiday.

The A/H1N1 flu vaccines can be inoculated to people above three years of age, one dose per person (15 micro-grams per dose, 0.5ml), in order to ensure the safety of the person being inoculated. Seasonal influenza vaccines approved by China also adopt the standard of one-dose-per-person sub-packaging.

It took 96 days after obtaining the virus strain for Hualan to receive the state’s approval to introduce the first batch of the vaccine to the public.

By Li Jing